Pfizer's suffering from generics, but 'innovation for growth'—not big M&A—is still the mantra - FiercePharma

1. Pfizer's suffering from generics, but 'innovation for growth'—not big M&A—is still the mantra  FiercePharma
2. Pfizer's earnings outlook disappoints after Viagra loses patent protection and Lyrica faces same fate  CNBC
3. Pfizer quarterly profit in line, touts pipeline of future products  Yahoo Finance
4. Pfizer Tops Q4 Earnings But Guides for Weaker 2019 as Lyrica Exclusivity Ends  TheStreet.com
5. Pfizer's Outlook Disappoints as Drugmaker Focuses on Pipeline  Bloomberg
6. View full coverage on Google News

from Top stories - Google News http://bit.ly/2G9KLRV